Stocks In Focus: FIS, BEBE, CTIC, WAG
Tuesday, July 06, 2021 8:20 AM

Related Stories

Fidelity National Information Services, Inc.  (NYSE: FIS) on Tuesday reaffirmed its outlook for the second quarter of 2010 for low single digit growth in adjusted revenues compared to $1.26 billion pro forma revenues in the second quarter of 2009, and adjusted EBITDA margin expansion of approximately 100 basis points compared to the pro forma EBITDA margin of 28.5% in the prior year period. In addition, the company announced that it expects to report second quarter adjusted earnings per share of $0.45 to $0.47. Analysts currently expect the company to report earnings of 46 cents per share on revenue of $1.28 billion. The company will announce second quarter financial results after the close of regular market trading on Tuesday, July 20, 2010. The company also announced the launch of its previously announced tender offer for the purchase of up to $2.5 billion of shares of its common stock. 

bebe stores, inc. (NASDAQ: BEBE) announced early Tuesday that it will discontinue operations of its PH8 division, allowing the company to focus its efforts on improving bebe sales and profitability as well as continuing to develop its 2b bebe concept, including the possible conversion of certain current PH8 stores to 2b bebe stores. The company estimates the total pre-tax cost associated with closing or converting its 48 PH8 stores will be approximately $17 million. Further, the company said that it currently anticipates its 2010 fiscal fourth quarter comparable store sales will be at the low end of the range previously provided and currently remains comfortable with the earnings guidance previously provided.

Cell Therapeutics, Inc. (NASDAQ: CTIC) said Tuesday that it has submitted an expanded Pediatric Investigation Plan to the European Medicines Agency, as part of the process for its submission for a Marketing Authorization Application for pixantrone in the E.U. for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma. The company intends to file the MAA later this year. The pediatric program will study pixantrone in pediatric patients aged 6 months to 18 years with the goal of determining the comparative safety and effectiveness of pixantrone compared to doxorubicin in pediatric lymphoid cancers. 

Walgreen Co. (NYSE: WAG) announced Tuesday that its same-store sales increased 2 percent in June. The company had June sales of $5.67 billion, an increase of 8.4 percent from $5.23 billion for the same month in 2009.

Disclosure: Author doesn't own any of the stocks discussed here.



Symbol :


Market news:

More news


    Closest Estimates

User SymbolConsen EPSEstimate EPSActual EPS
Jim OPNT$0.10$0.09$0.07
XXXXX MNT$0.33$0.33$0.35
XXXXX OPNT$0.10$0.05$0.07
XXXXX PETM$0.33$0.33$0.34
XXXXX JBX$0.70$0.82$0.80
XXXXX HPQ$0.69$0.70$0.70
XXXXX OPNT$0.10$0.09$0.07
XXXXX CHUX$0.31$0.35$0.36
XXXXX HPQ$0.69$0.70$0.70
XXXXX CRM$0.01$0.00$0.01

    Recent Estimates

AnalystFirm NameSymbolEPS Estimate
Richard WXXXXX RIMM$1.34
mikeXXXXX RIMM$1.34